Drug Price Transparency Bills May Be Empty Calories
Executive Summary
Price justification legislation is advancing in both chambers of Congress. But CBO scores them as no savings.
You may also be interested in...
Drug Pricing Policies Attached To Surprise Medical Billing Legislation
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.
Orphan Drug Makers Would Escape Price Reporting Requirements Under House Bill
Legislation pending in US House Energy and Commerce Committee would exempt drugs treating diseases with less than 200,000 patients from needing to justify price increases.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.